Navigation Links
MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
Date:1/13/2009

LONGMONT, Colo., Jan. 13 /PRNewswire/ -- A new bacterial identification test that rapidly identifies MRSA infections moved closer to market with conclusion of its first multicenter clinical trial, which was announced today by MicroPhage, Inc., http://www.microphage.com. The company also reported the trial results have surpassed its early-stage performance expectations.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/AQTU542)

The beta-site study evaluated MicroPhage's prototype assay to identify Staphylococcus aureus (staph) bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia (bacteria in the blood). The research precedes FDA-submission clinical studies, which are scheduled to begin early this year. Beta sites included Johns Hopkins University, Northshore University Healthcare (IL.), and the University of Maryland Medical School. More information on the study is available on the National Institute of Health's ClinicalTrials.gov website, study # NCT00814151.

According to Drew Smith, Ph.D, Director, Research and Development at MicroPhage, test performance at the three sites exceeded all study goals and performed at or near FDA requirements in more than 700 clinical samples. "Our prototype assay performed like a market-ready test for identification of MRSA, producing excellent results with regard to specificity," said Smith. "We are confident the final manufactured product will be robust and meet the demands of the clinical laboratory market and the scrutiny of the FDA." He added that the system is expected to be available to US hospitals later this year.

The field trials confirm previous performance studies reported in October at the prestigious joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America. That research showed the MicroPhage system provides results in five hours versus up to 48 hours for culture testing methods, and had an excellent detection rate for S. aureus bacteria of 93 percent while also determining methicillin resistance or susceptibility at greater than 98 percent reliability. Results of the beta trial were not available for release, pending final analysis and publication.

The MicroPhage system requires no instrumentation and is composed of two small reaction tubes for incubating blood-culture specimens. After five hours, the incubated samples are added to two dipstick-like detectors. One detector shows if the sample is infected with staph bacteria and the other measures antibiotic susceptibility/resistance.

MicroPhage has adapted bacteriophage-amplification technology, a natural biologic process, for identifying bacterial infections. "Phages" are bacteria-specific viruses that multiply aggressively when exposed to target bacteria. In the detection process, reaction of the bacteriophage proteins on the test strip indicates the sample is positive for staph bacteria. For susceptibility analysis, the organism in the sample is challenged with an antibiotic. Because phages depend on host bacteria for growth, any compound that kills or inhibits the microbe will stop phage growth. Only resistant strains allow multiplication of phages and yield a positive signal on the detector strip. Further information about the technology is available at http://www.microphage.com/technology.

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary bacteriophage-based amplification platform, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive diagnostic tests. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands of hospitals and laboratories of all sizes. For further information, go to http://www.microphage.com.


'/>"/>
SOURCE MicroPhage, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
2. Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
3. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
6. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
7. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
Breaking Medicine News(10 mins):